The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Picking the right small caps isn’t easy, and that’s exactly why StockStory exists - to help you focus on the best opportunities. That said, here are three Russell 2000 stocks to steer clear of and some alternatives to watch instead.

Wabash (WNC)

Market Cap: $308.7 million

With its first trailer reportedly built on two sawhorses, Wabash (NYSE: WNC) offers semi trailers, liquid transportation containers, truck bodies, and equipment for moving goods.

Why Do We Steer Clear of WNC?

1. Backlog has dropped by 36.2% on average over the past two years, suggesting it’s losing orders as competition picks up
2. Falling earnings per share over the last five years has some investors worried as stock prices ultimately follow EPS over the long term

At $7.56 per share, Wabash trades at 4.6x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than WNC.

LeMaitre (LMAT)

Market Cap: $2.03 billion

Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions.

Why Is LMAT Not Exciting?

1. Subscale operations are evident in its revenue base of $240.9 million, meaning it has fewer distribution channels than its larger rivals

LeMaitre’s stock price of $89.64 implies a valuation ratio of 35x forward P/E. To fully understand why you should be careful with LMAT, check out our full research report (it’s free for active Edge members).

Supernus Pharmaceuticals (SUPN)

Market Cap: $2.55 billion

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ: SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine.

Why Are We Out on SUPN?

1. Annual revenue growth of 5.7% over the last two years was below our standards for the healthcare sector
2. Smaller revenue base of $681.5 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
3. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

Supernus Pharmaceuticals is trading at $44.48 per share, or 16x forward P/E. Read our free research report to see why you should think twice about including SUPN in your portfolio.

High-Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.